| Waiting for trial results can be unnerving for investors and executives alike, even under the best of circumstances—but this year could prove make-or-break for some of the companies on our list. This includes a top contender for the market’s first NASH drug, treatments for respiratory illnesses and migraines, and potential blockbusters-in-waiting. And then there’s a new CAR-T being tested in solid tumors: small cell lung cancer linked to smoking, specifically. Our most-anticipated data readouts of 2020 are below, along with the week’s top stories. | |
|
Featured Story | | | Wednesday, January 29, 2020 GlaxoSmithKline’s respiratory blockbuster Advair may have once been a top target for generics, but now Novartis is backing out of its copycat program—and paying a hefty price. It's not just a blow to the Swiss drugmaker, but a word of caution for other would-be copycats. |
|
|---|
|
|  | [Webinar] Accelerating Approval for Cell and Gene Therapies Thursday, February 27 | 12pm ET / 9am PT Developers of cell and gene therapies can run into complex clinical and regulatory hurdles when bringing treatments to patients. Join experts from Cardinal Health Regulatory Sciences to explore critical factors that can help reduce the risk of failure and increase speed to market. |
Top Stories Of The Week Monday, January 27, 2020 Allergan has terminated a deal with AstraZeneca to clear a regulatory barrier to its pending merger with AbbVie. The terms of the termination return the rights to brazikumab to AstraZeneca but leave Allergan on the hook for the cost of development in Crohn’s disease and ulcerative colitis. What are some of the bigger data points for 2020? We share what we think will be the five most pivotal readouts for their respective companies (and stockholders). Monday, January 27, 2020 To battle the coronavirus emergency, Chinese government and medical experts are taking some unconventional measures, including publicly backing off-label use of a Big Pharma drug. AbbVie’s HIV combo therapy Kaletra (or Aluvia) is that med, and the Illinois pharma immediately responded with a million-dollar donation. Friday, January 24, 2020 Gilead is considering repositioning NUC inhibitor remdesivir as a treatment for the coronavirus now sweeping across parts of China. The antiviral last made headlines when Gilead tested it, with little success, as a treatment for Ebola virus. Tuesday, January 28, 2020 Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division. It also announced that its connected care businesses—including enterprise patient monitoring services and digital records—would see new management. Monday, January 27, 2020 Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis with a suite of phase 3 studies. Top-line data from one of those trials could help Olumiant prep for a U.S. filing, but does the latecomer really stand a chance against Sanofi and Regeneron's steamroller Dupixent? Tuesday, January 28, 2020 AbbVie will soon own Allergan’s prized Botox franchise, and along with its nearly $4 billion in sales, it will lay claim to a new $176 million plant at the site in Ireland where the blockbuster is exclusively produced. Friday, January 24, 2020 A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing, although don’t expect many megadeals. Tuesday, January 28, 2020 In Pfizer’s most recent clinical program dump, the New York pharma pulled the plug on several studies of its Merck KGaA-shared anti-PD-L1 drug Bavencio. Some cohorts of an early trial testing Bavencio alongside investigational OX40 agonist PF-04518600 and/or anti-4-1BB drug utomilumab (PF-05082566) have ended. Friday, January 24, 2020 Scientists at the Broad Institute and the Dana-Farber Cancer Institute screened thousands of existing drug compounds and unexpectedly found 49 they believe could be repurposed for treating cancer. They also identified novel targets that could aid in the development of new cancer drugs. |  | [Webinar] InCrowd’s 2020 Healthcare Predictions Tuesday, February 11 | 1pm ET / 10am PT How will 2020 change US healthcare? InCrowd’s physicians weigh in on what the new year will bring. Join Diane Hayes, PhD, InCrowd Co-Founder and Board Member and Daniel S. Fitzgerald, InCrowd CEO and President, for InCrowd’s 2020 Healthcare Predictions Webinar. Register Now! |
Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|---|
|
Resources Sponsored by: Quotient Sciences Tufts Center for the Study of Drug Development (CSDD) white paper sharing study results that indicate Quotient Sciences’ Translational Pharmaceutics® platform reduces development times by more than 12 months and lowers R&D costs by more than $100 million per approved new drug, compared to traditional multi-vendor development paradigms. Sponsored by: Benchling As emerging modalities transform the needs of life science R&D, how can biotech and pharma companies use modern software approaches to increase productivity and reach breakthroughs faster? Sponsored by: ICON Clinical Research Ltd The beginning of this digital transformation is well underway and is likely to accelerate. Read our white paper, “Digital Disruption in Biopharma: How Digital Transformation can reverse declining ROI on R&D,” to learn more. Sponsored by: Amazon Web Services From IoT to data management to high-performance computing and machine learning, leading life sciences organizations are using Amazon Web Services (AWS) to develop scalable, global, predictable, and secure solutions to modernize clinical trials while mitigating risks Sponsored by: EVERSANA How are your launch strategies can convert “innovation” into value for patients? Sponsored by: Metabolon Small or emerging pharmaceutical and biotech companies pursuing novel molecules and targets have two important goals: achieve clinical success and attract new rounds of funding. While there’s never a guarantee of either, certain actions can influence the outcome in your favor. Sponsored by: Catalent Learn how recent innovations in demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric. Sponsored by: Altran This whitepaper highlights the challenges of implementing the right digital twin strategy while providing key use cases in the manufacturing domain for which a digital twin is extremely useful and several examples of technology trends that will shape the future. Sponsored by: Catalent Pharma Solutions In this Q&A, four Catalent Biologics experts share how scale-up, regulatory expectations, demand forecasting and process validation all play a role in the success of a biologic when embarking upon the commercial manufacturing journey. |
|
